Angiogenesis inhibitors in the treatment of non-small cell lung cancer

Related Experiment Video

Updated: May 30, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Joline S W Lind1, Egbert F Smit

  • 1Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.

Therapeutic Advances in Medical Oncology
|July 27, 2011
PubMed

Insights

New treatments targeting angiogenesis, particularly the vascular endothelial growth factor (VEGF) pathway, show promise for advanced non-small cell lung cancer (NSCLC) where chemotherapy has plateaued.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Standard cytotoxic chemotherapy for advanced non-small cell lung cancer (NSCLC) has reached a therapeutic plateau.
  • Angiogenesis, driven by the vascular endothelial growth factor (VEGF) pathway, is crucial in NSCLC development and progression.
  • VEGF overexpression in NSCLC correlates with a poor prognosis, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review current angiogenesis inhibitors targeting the VEGF pathway for advanced NSCLC treatment.
  • To discuss the development and potential of VEGF-targeted therapies in NSCLC.

Main Methods:

  • Literature review of angiogenesis inhibitors focusing on the VEGF pathway in NSCLC.
  • Analysis of approved and investigational drugs targeting VEGF or its receptors.

Main Results:

  • Angiogenesis inhibitors targeting the VEGF pathway demonstrate significant promise in NSCLC treatment.
  • Bevacizumab, an anti-VEGF antibody, is approved for advanced NSCLC.
  • Several other VEGF pathway inhibitors are in late-stage clinical investigation.

Conclusions:

  • Targeting the VEGF pathway represents a promising therapeutic avenue for advanced NSCLC.
  • Further research and clinical trials are needed to address unresolved issues in VEGF-targeted therapy for NSCLC.
Keywords:
angiogenesis inhibitorsbevacizumabnon-small cell lung cancervascular endothelial growth factor

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.